UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
In a phase 2 trial in Chinese people with type 2 diabetes, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean body weight reduction of up to 9.8% after 24 weeks, showing improvements relative to placebo and semaglutide 1 mg
The safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical trials with triple-G agonists.
